MateiPaulSocoteanuMD

Oncology • Longview, TX

Texas Oncology Longview

Join to view full profile

Dr. Socoteanu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Socoteanu's full profile

Already have an account?

Office
1300 N 4th St
Longview, TX 75601
Phone+1 903-757-2122

Fax+1 903-252-6008
Is this information wrong?

Education & Training

Texas A&M College of Medicine-Scott and White Medical Center (Temple)Fellowship, Hematology and Medical Oncology, 2009
University of Tennessee Medical Center at KnoxvilleResidency, Internal Medicine, 2004 - 2007
University of Tennessee Medical Center at KnoxvilleInternship, Internal Medicine, 2004 - 2005
LSU School of Medicine in ShreveportClass of 2004

Certifications & Licensure

TX State Medical License 2008 - 2024
TN State Medical License 2006 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2

Publications & Presentations

PubMed

22 citations
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider, Jerome H. Goldschmidt, Jennifer L. Eisenstein, David Berz, Lasika Senevi...> ;Journal of Thoracic Oncology. 2021 Feb 1
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng...> ;The New England journal of medicine. 2018-09-25
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard ...> ;The New England journal of medicine. 2018-09-25
7 citations
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.
Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano, Daniel Haggstrom, Matei P. Socoteanu, David Smith, Christopher Dakhil, Kartik Kondur...> ;Frontiers in Oncology. 2018 Jul 24
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S,...> ;The New England journal of medicine. 2018-06-04
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D...> ;The New England journal of medicine. 2017-09-08
30 citations
c-Met targeted therapy of cholangiocarcinoma.
Matei P. Socoteanu, Frank E. Mott, Gianfranco Alpini, Arthur E. Frankel> ;World Journal of Gastroenterology. 2008 May 21
Join now to see all